Literatur
Brasure M, MacDonald R, Dahm P et al (2016) Newer medications for lower urinary tract symptoms attributed to benign prostatic hyperplasia: a review. Comparative effectiveness review, Bd. 178
D’Ancona C, Haylen B, Oelke M et al (2019) On behalf of the Standardisation Steering Committee ICS and the ICS Working Group on Terminology for Male Lower Urinary Tract & Pelvic Floor Symptoms and Dysfunction. Neurourol Urodyn 38(2):433–477
European Association of Urology (2021) EAU guideline on management of non-neurogenic male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO)
Gormley EA, Lightner DJ, Faraday M et al (2015) Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol 193(5):1572–1580
Kim HJ, Sun HY, Choi H et al (2017) Efficacy and safety of initial combination treatment of an alpha blocker with an anticholinergic medication in benign prostatic hyperplasia patients with lower urinary tract symptoms: updated meta-analysis. PLoS ONE 12:e169248
Lee SH, Byun SS, Lee SJ et al (2014) Effects of initial combined tamsulosin and solifenacin therapy for overactive bladder and bladder outlet obstruction secondary to benign prostatic hyperplasia: a prospective, randomized, multicenter study. Int Urol Nephrol 46(3):523–529
Reynard JM (2004) Does anticholinergic medication have a role for men with lower urinary tract symptoms/benign prostatic hyperplasia either alone or in combination with other agents? Curr Opin Urol 14(1):13–16
Wang YC, Chen YL, Huang CC et al (2019) Cumulative use of therapeutic bladder anticholinergics and the risk of dementia in patients with lower urinary tract symptoms: a nationwide 12-year cohort study. BMC Geriatr 18:380
Xin Z, Huang Y, Lu J et al (2013) Addition of antimuscarinics to alpha-blockers for treatment of lower urinary tract symptoms in men: a meta-analysis. Urology 82(2):270–277
Yu ZJ, Yan HL, Xu FH et al (2020) Efficacy and side effects of drugs commonly used for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Front Pharmacol 11:658
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
S. Schönburg: Referententätigkeit: Allergan, A.M.I., AstraZeneca, Boston Scientific. Beratertätigkeit: Omega Pharma. Die Autorin versichert, dass betreffs der im Artikel genannten Thematik keine Interessenskonflikte bestehen.
Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.
Additional information
QR-Code scannen & Beitrag online lesen
Rights and permissions
About this article
Cite this article
Schönburg, S. Prostataobstruktionsassoziierte Symptome der unteren Harnwege. Urologe 60, 1188–1191 (2021). https://doi.org/10.1007/s00120-021-01617-2
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00120-021-01617-2